Praram 9 Hospital Public Company (PR9) Fair Value & Analysis
Healthcare · TH · Market cap 14.2B THB
Fair value as of: Jul 16, 2026
From 26 valuation models · updated 25 days ago
Fair value updated Jul 16, 2026, revised from 22.37 THB to 20.22 THB (−9.6%) since Jun 24, 2026. Share price +4.5% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- A fairly wide model range (13.25 THB to 25.33 THB) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.
How to read this chart
60‑month range 8.62 THB – 25.74 THB · fair‑value band 13.25 THB – 25.33 THB · the 18.40 THB price screens below the 20.22 THB fair value. Dashed = 300-day average. As of Jul 16, 2026.
Analysis
Praram 9 Hospital Public Company (PR9) currently trades at 18.40 THB, while our model-based Fair Value estimate is 20.22 THB, implying the stock looks roughly 9.9% fairly valued today. The Quality Score stands at 66/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Praram 9 Hospital Public Company generated revenue of 5.4B THB at a net margin of 15.0%. Revenue grew 4.1% year over year. It earns a return on equity of 13.8%. The balance sheet holds a net cash position of 635M THB. Fundamentals as of Jul 16, 2026
Our scenario range runs from 13.25 THB (bear case) to 25.33 THB (bull case); at 18.40 THB, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 29% below its 52-week high and 19% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at 10%, PR9 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (19.48 THB) versus Asset-Based (5.01 THB). Highest evidence: Residual Income (76).
Notify me when PR9 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 66 · Market factors (momentum, volatility) 47
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Praram 9 Hospital Public Company Limited engages in hospital operations primarily in Thailand. The company operates medicine, surgery, diabetes and metabolic, spine, orthopedic, physical therapy and rehabilitation, chest and respiratory, neurology, thyroid and thyroid surgery, obstetrics gynecology, IVF, breast, oncocare, emergency, imaging, Lasik, skin and …
Full company description
Praram 9 Hospital Public Company Limited engages in hospital operations primarily in Thailand. The company operates medicine, surgery, diabetes and metabolic, spine, orthopedic, physical therapy and rehabilitation, chest and respiratory, neurology, thyroid and thyroid surgery, obstetrics gynecology, IVF, breast, oncocare, emergency, imaging, Lasik, skin and plastic surgery, mind, gastrointestinal and liver disease, dental, check-up, eye, pediatric, sleep, ear, nose, and throat centers, as well as vaccination and travel medicine, and traditional Chinese medicine clinics. It also engages in the operation of kidney disease and transplantation, cardiovascular, and pain management and wellness institutes. Praram 9 Hospital Public Company Limited was founded in 1992 and is based in Bangkok, Thailand.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Praram 9 Hospital Public Company reported revenue of 5.3B THB in FY2025 versus 3.0B THB in FY2021, a compound +15.3%/yr. Reported net income was 823M THB in FY2025, compounding +34.8%/yr from FY2021.
of which total revenue +10.0 pp · buybacks/dilution −1.1 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch PR9: get an alert when its fair value changes →
Peer Group
Medical Care Facilities · 261 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 45/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare Praram 9 Hospital Public Company with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Praram 9 Hospital Public Company (PR9) overvalued or undervalued?
What is the fair value of PR9?
What is the quality score of PR9?
What is the revenue of Praram 9 Hospital Public Company (PR9)?
What is the net profit margin of PR9?
Does Praram 9 Hospital Public Company pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Praram 9 Hospital Public Company and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.